Related Experiment Video
Updated: Jun 7, 2026
08:38
Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia
Published on: August 28, 2013
Triptorelin embonate: a 6-month formulation for prostate cancer
1University of Leeds, Leeds, UK. peter.whelan6@btinternet.com
Expert Opinion on Pharmacotherapy
|October 26, 2010
Summary
A new 6-month formulation of luteinizing hormone releasing hormone (LHRH) agonist, triptorelin embonate, offers similar efficacy to shorter-acting versions for prostate cancer treatment. This extended-release option may help reduce overtreatment and improve patient outcomes.
Area of Science:
- Endocrinology
- Oncology
- Pharmacology
Background:
- Luteinizing hormone releasing hormone (LHRH) agonists are crucial for androgen deprivation therapy in advanced prostate cancer.
- These agents also play a role in treating endometriosis, uterine fibroids, and central precocious puberty.
Purpose of the Study:
- To review the new 6-month sustained-release formulation of triptorelin embonate, an LHRH agonist.
- To evaluate its efficacy, side effect profile, and place in modern prostate cancer therapy.
Main Methods:
- The review focuses on triptorelin embonate 22.5 mg, a novel 6-month sustained-release LHRH agonist formulation.
- Comparison with existing 3-month preparations regarding duration of action, efficacy, and side effects.
Main Results:
- The 6-month triptorelin embonate formulation demonstrates a longer duration of action compared to the standard 3-month preparation.
- It exhibits comparable efficacy and side effect profiles to currently available treatments.
- Recent data suggest potential overtreatment with LHRH agonists, positioning the 6-month formulation within evolving therapeutic paradigms.
Conclusions:
- Triptorelin embonate 22.5 mg is a valuable new option for androgen deprivation therapy in prostate cancer.
- It is particularly beneficial as an adjunct to radiation and chemotherapy.
- The 6-month formulation offers similar therapeutic effects with potentially fewer side effects than existing options.
